CoChat

PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia

The DOI matches its Crossref record; 57 of the 60 references it cites were found in a registry or an index.

Abstract

Targeting B-cell receptor signaling using the PI3Kδ inhibitor idelalisib is a highly effective treatment option for relapsed/refractory chronic lymphocytic leukemia (CLL) patients. In addition to its direct impact on tumor cells, PI3Kδ inhibition can modulate the activity of regulatory T-cells (Tregs) resulting in enhanced anti-tumoral immune functions which may contribute to the success of PI3Kδ inhibitors in cancer therapy. The role of Tregs in CLL and their modulation by PI3Kδ inhibitors was so far poorly understood. Using the Eµ-TCL1 adoptive transfer model of CLL, we show that disease development induces the accumulation of activated and highly immunosuppressive Tregs. Depletion of CD25+ Tregs using anti-CD25 antibodies resulted in enhanced CD8+ T-cell activation, effector differentiation, and functional capacity. We further show that pharmacological inhibition of PI3Kδ effectively controlled disease and significantly decreased both CD25+ and CD25- Treg numbers, proliferation and activation status in CLL-bearing mice. Nonetheless, this PI3Kδ-mediated decrease in Tregs did not translate into better CD8+ T-cell function, as PI3Kδ inhibition concomitantly abrogated T-cell receptor signaling in CD8+ T-cells leading to decreased activation, effector cell differentiation and proliferation. Collectively, these data highlight the strong immunomodulatory effects of PI3Kδ inhibitors in CLL and are of relevance for a rational design of idelalisib-based combination therapies in CLL.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41375-018-0318-3

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 61

Metadata

Authors
Hanna, B. S., Roessner, P. M., Scheffold, A., Jebaraj, B. M. C., Demerdash, Y., Öztürk, S., Lichter, P., Stilgenbauer, S., & Seiffert, M.
Affiliations
  • German Cancer Research Center (DE)
  • University Hospital Ulm (DE)
Corresponding author
  • Hanna, Bola S.
  • Seiffert, Martina
Venue
Leukemia
Published
2018-12-20
Volume
33
Issue
6
Pages
1427-1438
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2904653639
Cited by
55
References
60
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 10 · 2022: 5 · 2021: 14 · 2020: 16 · 2019: 5
FWCI
4.98
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Leukemia (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Deutsche Forschungsgemeinschaft (SFB1074 project B1)
  • Bundesministerium für Bildung und Forschung (Precise, FIRE-CLL, Fire-CLL)
  • José Carreras Leukämie-Stiftung (R14/23)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
PI3Kδ inhibition, idelalisib, chronic lymphocytic leukemia, regulatory T cells, CD8+ T cell activation, effector T cell differentiation, T cell receptor signaling, immunomodulation, B cell receptor signaling, combination therapy
MeSH terms
Animals, Antineoplastic Agents, Cell Differentiation, Female, Humans, Lymphocyte Activation, Mice, Inbred C57BL, Purines, Tumor Cells, Cultured, Signal Transduction, Leukemia, Lymphocytic, Chronic, B-Cell, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Quinazolinones, Class I Phosphatidylinositol 3-Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.